Designing and reporting clinical trials on treatments for cutaneous leishmaniasis

Clinical Infectious Diseases

Volumn 51, Issue 4, 2010, Pages 409-419

  González, Urbà ^a   Pinart, Mariona ^a   Reveiz, Ludovic ^b   Rengifo Pardo, Monica ^c   Tweed, Jack ^c   Macaya, Antonio ^d   Alvar, Jorge ^e  

^a HOSPITAL PLATÓ   (Spain)

^b Sanitas Institute of Research ^*  (Colombia)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZITHROMYCIN; CETRIMIDE; CLOTRIMAZOLE; DAPSONE; FLUCONAZOLE; GAMMA INTERFERON; GARLIC EXTRACT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; ITRACONAZOLE; KETOCONAZOLE; LEISHMANIA VACCINE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MICONAZOLE; MILTEFOSINE; NATURAL PRODUCT; OMEPRAZOLE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; PENTOXIFYLLINE; PLACEBO; RIFAMPICIN; SODIUM CHLORIDE; STIBOGLUCONATE SODIUM; TRICHLOROACETIC ACID; UNINDEXED DRUG; UREA; ZINC SULFATE; ANTIPROTOZOAL AGENT;

CARBON DIOXIDE LASER; CLINICAL RESEARCH; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CRYOTHERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; FOLLOW UP; HONEY; HUMAN; HYPERTHERMIC THERAPY; LEISHMANIA; LEISHMANIA AETHIOPICA; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA TROPICA; METHODOLOGY; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN LEISHMANIASIS; LEISHMANIASIS, CUTANEOUS; MEDICAL RESEARCH; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTIPROTOZOAL AGENTS; BIOMEDICAL RESEARCH; HUMANS; LEISHMANIASIS, CUTANEOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77955703546     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655134     Document Type: Review

References (114)

1. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol 2006; 22:552-557.
2. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7:581-596.
3. World Health Organization. Control of leishmaniasis. Report by the Secretariat. 2007. http://apps.who.int/gb/ebwha/pdf-files/WHA60/A60-10-en.pdf. Accessed 7 July 2010.
4. Savioli L, Engels D, Daumerie D, et al. Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization. PLoS Med 2006; 3:e283.
5. World Health Organization (WHO). Report of the Fifth Consultatve Meeting on HIVLeishmania Co-infection. Addis Ababa, 20- 22 March 2007. WHO/CDS/NTD/IDM/ 2007. 2008.
6. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled trials. BMJ 2001; 323:42-46.
7. González U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008; 4:CD005067.
8. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed J. Interventions for New World cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009; 2:CD004834.
9. Schulz KF, Grimes D.A. Generation of allocation sequences in randomised trials: chance, not choice. Lancet 2002; 359:515-519.
10. Al-Fouzan AS, Al-Saleh QA, Najem NM, Rostom A.I. Cutaneous Leishmaniasis in Kuwait. Int J Dermatol 1991; 30:519-521.
11. Alkhawajah AM, Larbi E, Al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Ann Trop Med Parasitol 1997; 91:899-905.
12. Alrajhi AA, Ibrahim EA, de Vol EB, Khairat M, Faris RM, Maguire J.H. Fluconazole for the treatment of cutaneous leishmaniasis caused by leishmania major. N Engl J Med 2002; 346:891-895.
13. Alsaleh Qasem A, Dvorak R, Nanda A. Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait. Int J Dermatol 1995; 34:495-497.
14. Asilian A, Jalayer T, Whitworth G, Ghasemi RL, Nilforooshzadeh M, Olliaro P. A randomized, placebo-controlled trial of a twoweek regimen of aminosidine (paramomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995; 53:648-651.
15. Asilian A, Jalayer T, Nilforoosshzadeh M, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double- blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003; 81:353-359.
16. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (glucantime) vs. cryotherapy and intralesional meglumine antimoniate (glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43:281-283.
17. Asilian A, Sharif A, Faghihi G, Enshaeieh SH, Shariati F, Siadat A.H. Evaluation of CO2 laser efficacy in the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43:736-738.
18. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebocontrolled, randomized clinical trial. Clin Exp Dermatol 2006; 31:634-637.
19. Ben Salah A, Zakraoui H, Zaatour A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995; 53:162-166.
20. Chahed MK, Ben Salah A, Louzir H, et al. Efficacy of intra-lesional glucantime in the treatment of zoonotic cutaneous leishmaniasis in basic health care conditions [in French]. Arch Inst Pasteur Tunis 1999; 76: 13-18.
21. Dandashi A. Treatment of cutaneous leishmaniasis with fluconazole: a randomized double-blind, placebo-controlled trial. JEADV 2005; 19(suppl 2):43.
22. Dogra J, Aneja N, Lal Behari B, Mishra S.N. Cutaneous Leishmaniasis in India: Clinical Experience with Itraconazole. Int J Dermatol 1990; 29:661-662.
23. Dogra J. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85:212-213.
24. Dogra J. Cutaneous leishmaniasis in India: evaluation of oral drugs (dapsone versus itraconazole). Eur J Dermatol 1992; 2:568-569.
25. Dogra J, Saxena V.N. Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. Int J Parasitol 1996; 26: 1413-1415.
26. Esfandiarpour I, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002; 41:521-524.
27. Faghihi G, Tavakoli-kia R. Topical paromomycin vs intralesional meglumine antimoniate in cutaneous leishmaniasis. Clin Exp Dermatol 2003; 28:13-16.
28. Firooz A, Khatami A, Khamesipour A, et al. Intralesional injection of 2% zinc sulphate solution in the treatment of acute OldWorld cutaneous leishmaniasis: a randomized, double- blind, controlled clinical trial. J Drugs Dermatol 2005; 4:73-79.
29. Firooz A, Khamesipour A, Ghoorchi MH, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 2006; 142:1575-1579.
30. Gholami A, Khamesipour A, Momeni A, et al. Treatment of cutaneous leishmaniasis with 5% garlic cream: a randomized, double-blind study. Iranian J Dermatol 2000; 3:2-6.
31. Harms G, Chehade AK, Douba M, et al. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon in the local treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85: 214-216.
32. Iraji F, Vali A, Asilian A, Shahtalebi M, Momeni A.Z. Comparison of intralesionally injected Zinc sulphate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology 2004; 209:46-49.
33. Iraji F, Sadeghinia A. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a doubleblind, randomized trial in Isfahan, Iran. Ann Trop Med Parasitol 2005; 99:3-9.
34. Jaffar H. Rifampicin in cutaneous leishmaniasis- a therapeutic trial in Saudi Arabia. J Pakistan Assoc Dermatol 2006; 16:4-9.
35. Kochar DK, Aseri S, Sharma BV, Bumb RA, Mehta RD, Purohit S.K. The role of rifampicin in the management of cutaneous leishmaniasis. QJM 2000; 93:733-737.
36. Kochar DK, Saini G, Kochar SK, et al. A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J Vector Borne Dis 2006; 43:161-167.
37. Larbi EB, Al-Khawajah A, Al-gindan Y, Jain S, Abahusain A, Al-Zayer A. A randomized, double-blind, clinical trial of topical clotrimazole versus mizonazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. Am J Trop Med Hyg 1995; 52:166-168.
38. Layegh P, YazdanpanahMJ, Vosugh EM, Pezeshkpoor F, Shakeri M T, Moghiman T. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2007; 77:99-101.
39. Lynen L, Van Damme W. Local application of Diminazene aceturate: an effective treatment for cutaneous leishmaniasis? Ann Soc Belg Med Trop 1992; 72:13-19.
40. Mashood AA, Hussain K. Efficacy of allopurinol compared with pentostam in the treatment of old world cutaneous leishmaniasis. J Coll Physicians Surg Pak 2001; 11: 367-370.
41. Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007; 103:33-40.
42. Momeni AZ, Jalayer T, Emamjomeh M, et al. Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Arch Dermatol 1996; 132:784-786.
43. Momeni AZ, Reiszadae MR, Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and lowdose meglumine antimoniate. Int JDermatol 2002; 41:441-443.
44. Momeni AZ, Aminjavaheri M, Omidghaemi M.R. Treatment of cutaneous leishmaniasis with ketoconazole cream. JDermatolog Treat 2003; 14:26-29.
45. Munir A, Janjua SA, Hussain I. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Acta Dermatovenerol Croat 2008; 16:60-64.
46. Mutjaba G, Khalid M. Weekly versus fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis. Int J Dermatol 1999; 38:607-609.
47. Nassiri-Kashani M, Firooz A, Khamesipour A, et al. A randomized, double-blind, placebo- controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. JEADV 2005; 19:80-83.
48. Nilforoushzadeh M.A. Efficacy of combined triple therapy (paromomycin ointment, cryotherapy and intralesional glucantime) in comparison with intralesional glucantimefor treatment of acute cutaneous leishmaniasis. Iranian J Dermatol 2004; 3:136-139.
49. Nilforoushzadeh MA, Jaffary F, Reiszadeh M.R. Comparative effect of topical trichloroacetic and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Int J Pharmacol 2006; 2:633-636.
50. Nilforoushzadeh MA, Reiszadeh MR, Jafari F. Topical trichloroacetic A compared with intralesional glucantime injection in the treatment of acute wet cutaneous leishmaniasis: an open clinical trial. Iranian JDermatol 2003; 2:34-39.
51. Nilforoushzadeh MA, Jaffary F, Moradi S, Derakhshan R, Haftbaradaran E. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis. BMC Complement Altern Med 2007; 7:13.
52. Özgöztasi O, Baydar I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol 1997; 36: 61-63.
53. Reithinger R, Mohsen M, Wahid M, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 2005; 40:1148-1154.
54. Sadeghian G, Nilforoushzadeh M.A. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45:819-821.
55. Sadeghian G, Nilfroushzadeh MA, Siadat A.H. A comparison between intralesional hypertonic sodium chloride solution and meglumine antimoniate in the treatment of cutaneous leishmaniasis. Egyptian Dermatol Online 2006; 1:8.
56. Sadeghian G, Nilfroushzadeh MA, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol 2007; 32:371-374.
57. Salmanpour R, Handjani F, Noupisheh M.K. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat 2001; 12:159-162.
58. Salmanpour R, Razmavar MR, Abtahi N. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45:1115-1116.
59. Sharquie KE, Najim RA, Farjou I.B. A comparative controlled trial of intralesionally- administered zinc sulphate, hypertonic sodium chloride and pentavalent antimony compound against cutaneous leishmaniasis. Clin Exp Dermatol 1997; 22:169-173.
60. Sharquie KE, Najim RA, Farjou IB, Al-timimit D.J. Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. Clin Exp Dermatol 2001; 26:21-26.
61. Shazad B, Abbaszadeh B, Khamesipour A. Comparison of topical paromomycin sulfate (twice/day) with intralesionalmeglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol 2005; 15:85-87.
62. Zerehsaz F, Salmanpour R, Farhad H, et al. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran. Int J Dermatol 1999; 38:610-612.
63. Almeida R, D'Oliveira A Jr, Machado P, et al. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. J Infect Dis 1999; 180: 1735-1737.
64. Andersen EM, Cruz-Saldarriaga M, LLanos- Cuentas A, et al. Comparison of meglumine and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 2005; 72: 133-137.
65. Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimoniate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis 1994; 18:381-384.
66. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with the paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001; 65:466-470.
67. Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimoniate in the intitial treatment of cutaneous lesihmaniasis. Clin Infect Dis 2007; 44: 1549-1554.
68. Armijos RX, Weigel MM, Calvopiña M, Mancheno M, Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for NewWorld cutaneous leishmaniasis. Acta Trop 2004; 91:153-160.
69. Ballou WR, McClain JB, Gordon DM, et al. Safety and efficacy of high-dose sodiumstibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987; 2:13-16.
70. Convit J, Castellanos PL, Rondon A, et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987; 1:401-405.
71. Convit J, Castellanos PL, Ulrich M, et al. Immunotherapy of localized, intermediate, and diffuse forms of american cutaneous leishmaniasis. J Infect Dis 1989; 160:104-114.
72. Correia D, Macêdo VO, Carvalho EM, et al. Comparative study of meglumine antimoniate, pentamidine isothionate and aminosidine sulphate in the treatment of primary skin lesions caused by Leishmania (viannia) braziliensis. Rev Soc Bras Med Trop 1996; 29:447-453.
73. D'Oliveira A Jr, Machado PR, Carvalho E.M. Evaluating the efficacy of allopurinol for treatment of cutaneous leishmaniasis. Int J Dermatol 1997; 36:938-940.
74. Figueiredo Kopke LF, Siviero do Vale EC, Grossi Araujo M, Araújo Magalhâes P, Furtado T. Treatment of american tegumentary leishmaniasis with N-methyl-glucamine: double-blind study with doses of 14 mg/kg/ day and 28 mg/kg/day of antimoniate. An Bras Dermatol 1991; 66:87-94.
75. Franke ED, LLanos-Cuentas A, Echevarria J, et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 1994; 51:77-82.
76. Guderian RH, Chico ME, Rogers MD, Pattishall KM, Grogl M, Berman J.D. Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis. Am J Trop Med Hyg 1991; 45:92-97.
77. Hepburn NC, Tidman MJ, Hunter JA.A. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994; 88:700-703.
78. Krolewiecki AJ, Romero HD, Cajal SP, et al. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Am J Trop Med Hyg 2007; 77:640-646.
79. Llanos-Cuentas A, Echevarria J, Cruz M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 1997; 25:677-684.
80. Llanos-Cuentas A, Echevarria J, Seas C, et al Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis. Am J Trop Med Hyg 2007; 76:1128-1131.
81. Lobo IM, Soares MB, Correia TM, et al. Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy. Trans R Soc Trop Med Hyg 2006; 100:642-649.
82. Miranda-Verástegui C, LLanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 2005; 40:1395-1403.
83. Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007; 44:788-793.
84. Machado-Pinto J, Pinto J, da Costa CA, et al Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int J Dermatol 2002; 41:73-78.
85. Martinez S, Marr J. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992; 326:741-744.
86. Martinez S, Gonzalez M, Vernaza M.E. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin Infect Dis 1997; 24:165-169.
87. Navin TR, Arana BA, Arana FE, de Mérida AM, Castillo AL, Pozuelos J.L. Placebo-controlled clinical trial of meglumine antimoniate (glucantime) versus localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J TropMed Hyg 1990; 42:43-50.
88. Navin TR, Aran BA, Arana FE, Berman JD, Chajón J.F. Placebo-controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:528-534.
89. Neva FA, Ponce C, Ponce E, Kreutzer R, Modabber F, Olliaro P. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Trans R Soc Trop Med Hyg 1997; 91:473-475.
90. Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C. Treatment of american cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol Biol (Paris) 1997; 45:496-499.
91. Oster CN, Chulay JD, Hendricks LD, et al. American cutaneous leishmaniasis: a comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg 1985; 34:856-860.
92. Palacios R, Osorio LE, Grajales LF, Ochoa M.T. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimoniate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001; 64:187-193.
93. Saenz RE, Paz HM, Johnson CM, Narvaez E, de Vasquez A.M. Evaluation of the effectiveness and toxicity of pentostam and glucantime in the treatment of cutaneous leishmaniasis. Rev Med Panama 1987; 12:148-157.
94. Saenz RE, Paz H. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am JMed 1990; 89: 147-155.
95. Santos JB, de Jesus AR, Machado PR, et al Antimony plus recombinant human granulocyte- macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 2004; 190:1793-1796.
96. Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single- agent therapy for Colombian cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994; 88:695-698.
97. Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimoniate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998; 26:56-58.
98. Soto JM, Toledo JT, Gutierrez P, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002; 66: 147-151.
99. Soto J, Valda-Rodriguez L, Toledo J, et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.AmJ TropMed Hyg 2004; 71:577-581.
100. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266-1272.
101. Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78:210-211.
102. Velez I, Agudelo S, Hendrickx E, et al. Inefficacy of allopurinol as monotherapy for colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Int Med 1997; 126:232-236.
103. Schulz KF, Grimes D.A. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002; 359:614-618.
104. Day SJ, Altman D.G. Statistics notes: blinding in clinical trials and other studies. BMJ 2000; 321:504.
105. Higgins JPT, Altman D.G. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.0. Cochrane Collaboration, 2008. http:// www.cochrane-handbook.org/. Accessed 7 July 2010.
106. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2008; 8:458; author reply, 458-459.
107. Benatar SR, Fleischer T.E. Ethical issues in research in low-income countries. Int J Tuberc Lung Dis 2007; 11:617-623.
108. Cutts FT, Enwere G, Zaman SM, Yallop F.G. Operational challenges in large clinical trials: examples and lessons learned from the Gambia pneumococcal vaccine trial. PLoS Clin Trials 2006; 1:e16.
109. White N.J. Editorial: clinical trials in tropical diseases: a politically incorrect view. Trop Med Int Health 2006; 11:1483-1184.
110. Owens S, Stokes E, Mueller J. Re: Clinical trials in tropical diseases: a politically incorrect view. Trop Med Int Health 2007; 12:472.
111. Shih W.J. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 2002; 3:4.
112. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986; 105:429-435.
113. Schulz KF, Altman DG, Moher D, for the CONSORT Grou.P. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869.
114. Bigby M, Williams H. Appraising systematic reviews and meta-analyses. Arch Dermatol 2003; 139:795-798.